Abstract
Reproductive genetic carrier screening aims to offer couples information about their chance of having children with certain autosomal recessive and X-linked genetic conditions. We developed a gene list for use in “Mackenzie’s Mission”, a research project in which 10,000 couples will undergo screening. Criteria for selecting genes were: the condition should be life-limiting or disabling, with childhood onset, such that couples would be likely to take steps to avoid having an affected child; and/or be one for which early diagnosis and intervention would substantially change outcome. Strong evidence for gene-phenotype relationship was required. Candidate genes were identified from OMIM and via review of 23 commercial and published gene lists. Genes were reviewed by 16 clinical geneticists using a standard operating procedure, in a process overseen by a multidisciplinary committee which included clinical geneticists, genetic counselors, an ethicist, a parent of a child with a genetic condition and scientists from diagnostic and research backgrounds. 1300 genes met criteria. Genes associated with non-syndromic deafness and non-syndromic differences of sex development were not included. Our experience has highlighted that gene selection for a carrier screening panel needs to be a dynamic process with ongoing review and refinement.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others
References
Henneman L, Borry P, Chokoshvili D, Cornel MC, van El CG, Forzano F, et al. Responsible implementation of expanded carrier screening. Eur J Hum Genet. 2016;24:e1–e12.
Zlotogora J, Grotto I, Kaliner E, Gamzu R. The Israeli national population program of genetic carrier screening for reproductive purposes. Genet Med. 2016;18:203–6.
Commission HG. Increasing options, informing choice: a report on preconception genetic testing and screening. Human Genetics Commission, London. 2011.
ACOG. Committee Opinion No. 690: carrier screening in the age of genomic medicine. Obstet Gynecol. 2017;129:e35–e40.
RANZCOG. Genetic Carrier Screening. 2019. https://ranzcog.edu.au/RANZCOG_SITE/media/RANZCOG-MEDIA/Women%27s%20Health/Statement%20and%20guidelines/Clinical-Obstetrics/Genetic-carrier-screening(C-Obs-63)New-March-2019_1.pdf?ext=.pdf.
Delatycki M, Alkuraya F, Archibald A, Castellani C, Cornel M, Grody W, et al. International perspectives on the implementation of reproductive carrier screening. Prenat Diagn. 2020;40:301–10.
Rose NC. Expanded carrier screening: too much of a good thing? Prenat Diagn. 2015;35:936–7.
Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, et al. A review of gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017;18:441.
Strande NT, Riggs ER, Buchanan AH, Ceyhan-Birsoy O, DiStefano M, Dwight SS, et al. Evaluating the clinical validity of gene-disease associations: an evidence-based framework developed by the clinical genome resource. Am J Hum Genet. 2017;100:895–906.
Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat. 2000;15:228–37.
Xu Z, Chen W, Merke DP, McDonnell NB. Comprehensive mutation analysis of the CYP21A2 gene: an efficient multistep approach to the molecular diagnosis of congenital adrenal hyperplasia. J Mol Diagn. 2013;15:745–53.
Prior TW, Nagan N, Sugarman EA, Batish SD, Braastad C. Technical standards and guidelines for spinal muscular atrophy testing. Genet Med. 2011;13:686–94.
Bahlo M, Bennett MF, Degorski P, Tankard RM, Delatycki MB, Lockhart PJ. Recent advances in the detection of repeat expansions with short-read next-generation sequencing. F1000Res. 2018;7:F1000 Faculty Rev-736.
Schuurmans J, Birnie E, Lvd Heuvel, Plantinga M, Lucassen A, Dvd Kolk, et al. Feasibility of couple-based Expanded Carrier Screening offered by general practitioners. Eur J Hum Genet. 2019;27:691–700.
Plantinga M, Birnie E, Schuurmans J, Buitenhuis AH, Boersma E, Lucassen AM, et al. Expanded carrier screening for autosomal recessive conditions in health care: arguments for a couple-based approach and examination of couples’ views. Prenat Diagn. 2019;39:369–78.
Lynch FL, Himes P, Gilmore MJ, Morris EM, Schneider JL, Kauffman TL, et al. Time costs for genetic counseling in preconception carrier screening with genome sequencing. J Genet Couns. 2018;27:823–33.
Sherman SL. Premature ovarian failure in the fragile X syndrome. Am J Med Genet. 2000;97:189–94.
Hagerman RJ, Leavitt BR, Farzin F, Jacquemont S, Greco CM, Brunberg JA, et al. Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet. 2004;74:1051–6.
Plantinga M, Birnie E, Abbott KM, Sinke RJ, Lucassen AM, Schuurmans J, et al. Population-based preconception carrier screening: how potential users from the general population view a test for 50 serious diseases. Eur J Hum Genet. 2016;24:1417–23.
Ekstein J, Katzenstein H. The Dor Yeshorim story: community-based carrier screening for Tay-Sachs disease. Adv Genet. 2001;44:297–310.
Online Mendelian Inheritance in Man, OMIM®: McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD), https://omim.org/. [Accessed on 30/07/2018].
Chokoshvili D, Vears D, Borry P. Expanded carrier screening for monogenic disorders: where are we now? Prenat Diagn. 2018;38:59–66.
Mastantuoni E, Saccone G, Al-Kouatly HB, Paternoster M, D’Alessandro P, Arduino B, et al. Expanded carrier screening: a current perspective. Eur J Obstet Gynecol Reprod Biol. 2018;230:41–54.
Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S, et al. The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Genet. 2017;136:665–77.
Archibald AD, Smith MJ, Burgess T, Scarff KL, Elliott J, Hunt CE, et al. Reproductive genetic carrier screening for cystic fibrosis, fragile X syndrome, and spinal muscular atrophy in Australia: outcomes of 12,000 tests. Genet Med. 2018;20:513–23.
Holm IA, Yu TW, Joffe S. From sequence data to returnable results: ethical issues in variant calling and interpretation. Genet Test Mol Biomark. 2017;21:178–83.
Ghiossi CE, Goldberg JD, Haque IS, Lazarin GA, Wong KK. Clinical utility of expanded carrier screening: reproductive behaviors of at-risk couples. J Genet Counsel. 2018;27:616–25.
Lane H. Do deaf people have a disability? Sign Lang Stud. 2002;2:356–79.
Ladd P. Deafhood: a concept stressing possibilities, not deficits. Scand J Public Health. 2005;33(66_suppl):12–7.
Terry D, Lê Q, Nguyen H, Malatzky C. Misconceptions of the deaf: giving voice to the voiceless. Health, Cult Soc. 2017;9:47–61.
Carpenter M. The “normalization” of intersex bodies and “othering” of intersex identities in Australia. J Bioethical Inq. 2018;15:487–95.
Sparrow R. Gender eugenics? The ethics of PGD for intersex conditions. Am J Bioeth. 2013;13:29–38.
Parens E, Asch A. Disability rights critique of prenatal genetic testing: reflections and recommendations. Ment Retard Dev Disabil Res Rev. 2003;9:40–7.
Acknowledgements
We thank the following clinicians for advice on genes in their area of expertise; Stephen Alexander, Janice Fletcher, Paul Gray, Lilian Johnstone, Ian Kerridge, Andrew Mallett, John Massie, Hugh McCarthy, Vanessa Morgan, Philip Robinson, Monique Ryan, Peter Trnka, Jan Walker, Bridget Wilcken. We thank Morgan Carpenter for a submission on genes involved in differences of sex development. We thank Richard Allcock, Michael Fietz and Georgina Hollingsworth for helpful comments. We thank members of the NHMRC Centre for Research Excellence in Genetic Eye Diseases (APP1116360) for comment on ocular genes under consideration.
Funding
The Australian Reproductive Genetic Carrier Screening Project is funded by Australian Government’s Medical Research Future Fund as part of the Australian Genomics Health Futures Mission (GHFM73390 (MRFF- G-MM)). NGL is supported by Australian National Health and Medical Research Council Fellowship APP1117510.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Kirk, E.P., Ong, R., Boggs, K. et al. Gene selection for the Australian Reproductive Genetic Carrier Screening Project (“Mackenzie’s Mission”). Eur J Hum Genet 29, 79–87 (2021). https://doi.org/10.1038/s41431-020-0685-x
Received:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41431-020-0685-x
This article is cited by
-
From screening to strategy: Clinical implications of COL4A3/COL4A4 variants found in reproductive genetic testing
European Journal of Human Genetics (2026)
-
Unexpected genotypes associated with severe paediatric conditions identified in a healthy population cohort
European Journal of Human Genetics (2026)
-
Editorial: severity in a genomic age
European Journal of Human Genetics (2025)
-
Perceptions of severity and their influence on reproductive decision-making following reproductive genetic carrier screening
European Journal of Human Genetics (2025)
-
Expanding carrier screening: beyond the genes, to include underrepresented ancestries
npj Genomic Medicine (2025)


